

Table of Contents

Author Acknowledgments.....	ix
SECTION I: Risk Management Regulations	1
Chapter 1 Risk Management Regulations in the US.....	3
<i>Brande Yaist, MS; Debra Porter, MS; Debashish Dey, MD, PhD, MPH; and Nayan Achayara MBBS, MRCP, MFPM</i>	
Chapter 2 Regulations Related to Risk Management in Japan.....	39
<i>Yong Huang, MD, PhD; Krishna Babadursingh, MD, FRCS, MBA, LLB, FFPM; and Hiroshi Nakane</i>	
Chapter 3 European Experience with Additional Risk Minimization and its Impact on Benefit-Risk.....	49
<i>Darin Oppenheimer DRSc, FRAPS, RAC and George Cusatis MS, RAC</i>	
Chapter 4 Risk Management of Medicines and Biologicals in Australia.....	59
<i>Judy Bingham, MHA, GAICD</i>	
Chapter 5 Risk Management in Canada.....	71
<i>David Konadu, MSc, MASc</i>	
SECTION II: Benefit-Risk Management Principles and Practices	83
Chapter 6 The Impact of Preclinical Planning and Study Outcome on the Risk Management of Biologicals.....	85
<i>Michael Engwall, DVM, PhD, DSP</i>	
Chapter 7 Risk Management in Medical Devices and Artificial Intelligence.....	99
<i>Leo Hovestadt, MSc</i>	
Chapter 8 Quality Risk Management: A Gateway to Quality by Design.....	121
<i>Beat Widler, PhD, dipl. pharm. med., and Peter Schiemann, PhD, MBA</i>	
Chapter 9 Quality Management Systems for Medical Devices	133
<i>Russ Roberson, PhD, MBA, MScME, BScAgE</i>	
Chapter 10 Risk Management Principles and Processes for OTC Medicines.....	153
<i>Michael Steinbuch, PhD, FISPE, Matthew Francis, MS, PhD, and Andrej Miotk, PhD</i>	

Chapter 11	Clinical Evaluation Reports	165
	<i>Leo Hovestadt, MSc</i>	
Chapter 12	EU Postauthorization Safety Studies, US Postmarket Requirement, and US Postmarket Commitment	181
	<i>Tara Isherwood, MSc, BSc (Hons) and Mark Heinemann, BSc</i>	
Chapter 13	Minimizing and Monitoring Safety	199
	<i>Karin de Haart, MSc, Nadja Merkusheva, MD, Bernadette Dwan, BSc, Mpharm, MPSI, Lisette Hoogendoorn, PhD, and Priscilla Velentgas, PhD</i>	
Chapter 14	Use of Pregnancy Exposure Registries and Outcomes Studies for Risk Management ...	213
	<i>Jessica D. Albano, PhD, MPH, Angie Graves, MBA, MLS(ASCP), Sara Ephross, PhD, Brian Buysse, PhD and Tara Isherwood, MSc</i>	
Chapter 15	Clinical Evidence and Acceptable Benefit–Risk Evaluation	225
	<i>Leo Hovestadt, MSc</i>	
Chapter 16	Benefit-Risk Assessment: Art or Science?	239
	<i>Mariette Boerstoeel-Streefland, MD, MSc, MBA</i>	
Chapter 17	Risk Management in the Future: Expanding the Use of Electronic Health Records in Drug Development	249
	<i>Tjeerd–Pieter van Staa, MD, MSc, MA, PhD</i>	
SECTION III: Case Studies in Risk Assessment and Management		257
Chapter 18	Postmarket Pharmacoepidemiology Database Study Development to Evaluate Long-Term Drug Safety—An Example, Prolia	259
	<i>Fei Xue, MD, MSC, ScD</i>	
Chapter 19	EHR Use for Stimulated Reporting of Adverse Drug Events	269
	<i>Angela Walker, MD and Richard Loomis, MD</i>	
Chapter 20	RM During Peri-Approval Process: A Case Study of Actonel	283
	<i>Bruce R. DeMark, PhD</i>	
SECTION IV: Risk Communication, Dissemination, and Implementation		307
Chapter 21	Social Science Theory as a Framework for Designing and Evaluating Pharmaceutical Risk Management Dissemination and Implementation Strategies	309
	<i>Elaine H. Morrato, DrPH, MPH, CPH</i>	
Chapter 22	Using Mixed Methods to Evaluate Therapeutic Risk Minimization Programs: An Introduction and Case Study	333
	<i>Meredith Y. Smith, PhD, MPA, FISPE</i>	

SECTION V: REMS343

Chapter 23	Developing, Implementing, and Operating REMS Programs345
	<i>Paul Sheehan, MSJ, BSc, Lindsay Crampton, BSc, and Jemma Contreras, PhD, BSc</i>

Figures

Figure 1-1.	Overview of Risk Management5
Figure 1-2.	Safety Focus Throughout a Product's Lifecycle6
Figure 1-3.	Comparison of Monitoring and Control for a Traditional Product Launch versus a Product Launched With a Risk Management Plan7
Figure 1-4.	US Drug Regulation Advancements19
Figure 1-5.	Distribution of Combinations of Risk Management Elements Required by FDA (based on 2022 Active REMS Elements Combinations)22
Figure 1-6.	Comparison of Combination of Active REMS Elements 2008–10 and 201123
Figure 1-7.	Assessment of Effectiveness of REMS Medication Guide25
Figure 1-8.	Example of a REMS Assessment Implementation Timeline27
Figure 1-9.	FDA Postmarket Commitments and Requirements by Year29
Figure 1-10.	FDA Postmarket Safety Requirements by Type30
Figure 1-11.	History of the Sentinel Initiative32
Figure 1-12.	Overview of the Mini-Sentinel Safety Question Evaluation Process33
Figure 2-1.	Postapproval Surveillance System42
Figure 2-2.	Timeline for Postapproval Surveillance System*43
Figure 3-1.	Process for Developing a Risk Minimization Plan54
Figure 3-2.	Sample Benefit-Risk Profile Template55
Figure 3-3.	Benefit-Risk and Risk Minimization Process56
Figure 4-1.	Risk Management Overview (AS/NZS ISO 31000:2018)60
Figure 5-1.	Risk Management Process77
Figure 7-1.	Risk Management Process Steps102
Figure 7-2.	Risk Management Flow Using Hazard Analysis Technique103
Figure 7-3.	ISO 14971 Integration with Regulations and Standards111
Figure 7-4.	ISO 13485 Activities Related to Risk Management113
Figure 7-5.	Medical Device Use116
Figure 7-6.	Relation Between ISO 14971 and IEC 62366-1117
Figure 8-1.	Failure Mode and Effect Analysis (FMEA) Cycle124
Figure 8-2.	Three-Step RPN-based Risk Evaluation127
Figure 8-3.	Example of QRM in Action128
Figure 9-1.	Example of FDA Medical Device Classifications134
Figure 9-2.	Seven Risks of Medical Devices139
Figure 9-3.	The Risk Cycle141
Figure 9-4.	Generic SWEATT Model143
Figure 9-5.	Software Product Design SWEATT Model: Before147
Figure 9-6.	Software Product Design SWEATT Model: After148
Figure 9-7.	Product Risk SWEATT Model150
Figure 10-1.	Shifting Safety Focus as Medicines Mature154
Figure 11-1.	Clinical Investigation Registration Requirements175
Figure 12-1.	Noninterventional Postauthorization Safety Study Requirements185
Figure 12-2.	Endorsement for Single-Country Postauthorization Safety Studies Procedure189
Figure 12-3.	Module I Requirement Compliance Approach192
Figure 12-4.	Activities Impacting PV System Quality193
Figure 13-1.	Asking the Right Questions206

Figure 15-1. MDR Needs to Set a High Standard of Quality and Safety.....	226
Figure 15-2. MDR Clinical Evidence Objectives Per Device Life Cycle Phase	227
Figure 15-3. Valid Clinical Association	230
Figure 15-4. Technical Performance.....	231
Figure 15-5. Clinical Performance.....	231
Figure 15-6. Clinical Evidence Example for Radiation Treatment Planning	232
Figure 15-7. Endpoints for Clinical Evidence.....	233
Figure 15-8. MDR Requirements Related to Endpoints for Clinical Evidence.....	234
Figure 15-9. Acceptable Benefit-Risk	237
Figure 18-1. Time at Risk Estimate Based on On-Treatment and Post-Treatment Period for a Patient Receiving One Dose of Bisphosphonate Before Receiving One Dose of Prolia	263
Figure 19-1. PASP Clinical Decision Support Notification in the Practice Fusion EHR.....	276
Figure 19-2. Screenshot of Safety Surveillance Interface in Practice Fusion EHR	277
Figure 22-1. Types of Outcomes in RM Program Evaluation Research by Data Collection Method (Quantitative Versus Qualitative) (per GVP Module XVI Revision 3).....	334
Figure 22-2. An Embedded Mixed Methods Design with Complementarity Model to Evaluate the Effectiveness of the Risk Minimization Program for Product C.	337
Figure 23-1. Key Milestones in Developing, Implementing, and Operating a REMS: Brand Drug	348
Figure 23-2. Key Milestones in Developing, Implementing, and Operating a REMS: Generic Drugs.....	349
Figure 23-3. FDA Engagement Timeline	350
Figure 23-4. FDA Engagement for ANDA REMS.....	351
Figure 23-5. Services Involved in a Typical ETASU REMS.....	352
Figure 23-6. Services Involved in a Typical ETASU REMS: Example	353
Figure 23-7. Integration of REMS with Other Launch Activities.....	354
Figure 23-8. REMS Assessment Categories	355

Tables

Table 1-1. Timeline of US Drug Regulation Advancements.....	11
Table 1-2. Example Framework of FDA Risk Management Guidance and Regulations	13
Table 1-3. Legacy Pharmaceutical Products Deemed to Have a REMS Following FDAAA Implementation.....	20
Table 1-4. Examples of Triggers for FDA Requiring a REMS.....	21
Table 1-5. Example of a REMS Implementation Plan	28
Table 1-6. FDA Benefit-Risk Framework.....	35
Table 2-1. Regulatory Reporting of ICSRs for Investigational drugs	40
Table 2-2. Foreign Safety Measures Report and Research Report.....	41
Table 2-3. Regulatory Reporting of Postmarket Adverse Drug Reactions in Japan.....	44
Table 2-4. Regulatory Reporting of Postmarket Infections in Japan.....	45
Table 4-1. Reporting Requirements for Biologicals	65
Table 6-1. Summary Elements of an ETLA.....	86
Table 6-2. Factors Affecting the Safety Margin Calculations for FIH	92
Table 6-3. Hypothetical Risk Management Strategy for GLP-1 Agonist Biotherapeutics.....	93
Table 7-1. Contents of ISO 14971:2019.....	100
Table 7-2. Hazard Analysis Table	104
Table 7-3. Risk Management File Contents.....	105
Table 7-4. Example Severity Levels	107
Table 7-5. Example Probability Of Occurrence Levels.....	107
Table 7-6. Risk Evaluation Matrix.....	108

Table 7-7.	Example Acceptability Legend	108
Table 8-1.	Traditional Quality Management vs. QRM Approach	129
Table 10-1.	Examples of Risk Mitigation and Monitoring	160
Table 11-1.	Clinical Evidence Premarket Documentation Requirements	167
Table 11-2.	Clinical Evidence Postmarket Documentation Requirements	167
Table 11-3.	Clinical Evidence Element General Safety and Performance Requirements	167
Table 11-4.	Clinical Evidence Element not in General Safety and Performance Requirements	172
Table 11-5.	Clinical Evidence Elements for Medical Device Software	173
Table 11-6.	Clinical Development Plan with R-IDEAL Endpoints	176
Table 12-1.	Categories of PASS	184
Table 12-2.	Summary of Applicable Regulatory Requirements for PASS Conducted in the EU	184
Table 12-3.	Regulatory Requirements for Noninterventional PASS	187
Table 12-4.	GVP Module I: Purpose and Applicability to PASS	190
Table 12-5.	GVP Modules II, IV, V and VI: Purposes and Applicability to PASS	191
Table 12-6.	Management of Adverse Events for NI PAS with a Design Based on Primary Data Collection	194
Table 12-7.	Obligations to Consider for Conduct of US PMS	195
Table 15-1.	Medical Device Clinical Evidence Requirements	228
Table 15-2.	Medical Device Software Clinical Evidence Requirements	229
Table 15-3.	Medical Device Clinical Evidence Requirements for Quality and Quantity	230
Table 19-1.	Adverse Drug Event Detection and Reporting Methods	271
Table 19-2.	Comparison of Current and Proposed Programs	278
Table 20-1.	Combined Osteoporosis Treatment and Prevention Trials including Hip Fracture Trials	284
Table 20-2.	Lung Cancer in Risedronate Phase III PMO/CIO and HIP Fracture Trials	285
Table 20-3.	Distribution of Cancer Cases by COSTART: Ten Combined Risedronate Trials	286
Table 20-4.	GI Cancer in Combined Risedronate Phase III PMO/CIO and Hip Fracture Trials	287
Table 20-5.	FDA Statistical Analysis of Lung Cancer by Smoking History, Age, and Risedronate Dose in Risedronate Clinical Studies	287
Table 20-6.	Observed to Expected Lung Cancer Cases in Combined Risedronate Studies Based on the SEER Database (1988-1992) for US White Women	288
Table 20-7.	Distribution of Lung Cancer Based on Best Available Evidence	289
Table 20-8.	Categorization of Lung Cancer Data	290
Table 20-9.	Lung Cancers Excluding Cases < 6 Months After Dosing	290
Table 20-10.	Time of Diagnosis for 59 Cases of Lung Cancer	291
Table 20-11.	Incidence of Lung Cancer Based on 1,000 Person-Years of Observation	292
Table 20-12.	Cancer Cases by Site	294
Table 20-13.	Anticipated Deaths Due to Lung Cancer in Mortality Follow-Up Studies RVN, RON, and RHN	295
Table 20-14.	Patient-Years of Follow-up for RON009393, RVN008993, and RHN009193	296
Table 20-15.	“On-Study” Mortality Studies RON009393, RVN008993, and RHN009193	297
Table 20-16.	Estimated Mortality Due to Lung Cancer (Assumes RR* of 1.0 During “Off-Study” Follow-up of Non-incident Lung Cancer Cases, Studies RON009393, RVN008993, and RHN009193)	298
Table 20-17.	Estimated Mortality Due to Lung Cancer (Assumes RR* of 2.0 during “Off-Study” Follow-up of Non-incident Lung Cancer Cases, Studies RON009393, RVN008993, and RHN009193)	298
Table 20-18.	Mortality Comparisons Across Treatment Groups - All Cause through December 31, 1997 (Intent-to-treat)	299

Table 20-19. Mortality Comparisons Across Treatment Groups - All Cause through December 31, 1998 (Intent-to-treat).....	300
Table 20-20. Mortality Comparisons Across Treatment Groups - Any Cancer Listed on the Death Certificate through December 31, 1997 (Intent-to-treat).....	301
Table 20-21. Mortality Comparisons Across Treatment Groups - Lung Cancer Listed on the Death Certificate through December 31, 1997 (Intent-to-treat).....	302
Table 20-22. Accountability of the 42 Patients with Lung Cancer Reported in the Clinical Database.....	303
Table 20-23. Analysis of Lung Cancer Mortality through 1997 in Current or Previous Smokers.....	303
Table 20-24. Mortality Comparisons Across Treatment Groups - Lung Cancer Listed on the Death Certificate Through December 31, 1997 Among Patients Without a Diagnosis of Lung Cancer, according to the Clinical Database (Intent-to-treat).....	304
Table 21-1. The Innovation (Desired Risk Mitigation Behavior)	320
Table 21-2. Communication Channels	322
Table 21-3. Time and the Adoption Curve	323
Table 21-4. The Social System	325
Table 22-1. Components of the Proposed Risk Minimization Program for Product C in the EU.	336
Table 22-2. Evaluation Dimensions, Quantitative and Qualitative Measures, and Corresponding Data Sources for the Mixed Methods Evaluation of the RM Program for Product C Using the RE-AIM QuEST Framework.....	338
Index.....	361

Author Acknowledgments

RAPS and lead editor, J. Michael Sprafka, MPH, PhD, thank the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to this third edition of *Risk Management Principles for Devices and Pharmaceuticals*.

Nayan Achayara, MBBS,
MRCP, MFPM
Chapter 1

Jessica D. Albano, PhD, MPH
VP, Epidemiology & Analytics
Syneos Health
Chapter 14

Krishna Bahadursingh, MD,
FRCS, MBA, LLB, FFPM
Head of WorldWide Patient
Safety-Japan
Bristol Myers Squibb

Judy Bingham, MHA, GAICD
Executive Director
Easington Pty Ltd
Chapter 4

Mariette Boerstoele-Streefland,
MD, MSc, MBA
Chief Safety Officer, SVP
Patient Safety
AstraZeneca
Chapter 16

Brian Buysse, PhD
Senior Director, Epidemiology
Syneos Health
Chapter 14

Jemma Contreras, PhD
Advisory Group Lead, R&D
Consulting
Syneos Health
Chapter 23

Lindsay Crampton, BSc
Advisory Group Lead, Risk
& Program Management,
Consulting
Syneos Health
Chapter 23

George Cusatis MS, RAC
Sr. Regulatory Affairs Manager
Medtronic
Chapter 3

Karin de Haart, MSc
Product Strategy Lead
IQVIA
Chapter 13

Bruce R. DeMark, PhD
Retired Research Fellow
Procter & Gamble
Pharmaceuticals
Chapter 20

Debashish Dey, MD, PhD,
MPH
Vice President & Head, Drug
Safety & Pharmacovigilance
Intellia Therapeutics

Bernadette Dwan, BSc,
Mpharm, MPSI
Product Strategy Lead
IQVIA
Chapter 13

Michael Engwall, DVM, PhD,
DSP
Chapter 6

Sara Ephross, PhD
Senior Director, Epidemiology
Syneos Health
Chapter 14

Matthew Francis, MS, PhD
Epidemiologist
Procter and Gamble
Chapter 10

Angie Graves, MBA,
MLS(ASCP)
Senior Director, Business
Operations, Real World &
Late Phase
Syneos Health
Chapter 14

Mark Heinemann, BSc
Associate Director, Regulatory
Advice & Delivery
Syneos Health France SARL
Chapter 12